No biomarker
No biomarker
|
Fallopian Tube Cancer
Fallopian Tube Cancer
|
|
No biomarker
No biomarker
|
Fallopian Tube Cancer
Fallopian Tube Cancer
|
|
No biomarker
No biomarker
|
Fallopian Tube Cancer
Fallopian Tube Cancer
|
Mvasi (bevacizumab biosimilar)
|
No biomarker
No biomarker
|
Fallopian Tube Cancer
Fallopian Tube Cancer
|
Aybintio (bevacizumab biosimilar)
|
No biomarker
No biomarker
|
Fallopian Tube Cancer
Fallopian Tube Cancer
|
Onbevzi (bevacizumab biosimilar)
|
BRCA1 mutation
BRCA1 mutation
|
Fallopian Tube Cancer
Fallopian Tube Cancer
|
|
BRCA2 mutation
BRCA2 mutation
|
Fallopian Tube Cancer
Fallopian Tube Cancer
|
|
No biomarker
No biomarker
|
Fallopian Tube Cancer
Fallopian Tube Cancer
|
|
BRCA2 mutation
BRCA2 mutation
|
Fallopian Tube Cancer
Fallopian Tube Cancer
|
|
BRCA1 mutation
BRCA1 mutation
|
Fallopian Tube Cancer
Fallopian Tube Cancer
|
|
|
Fallopian Tube Cancer
Fallopian Tube Cancer
|
|
No biomarker
No biomarker
|
Fallopian Tube Cancer
Fallopian Tube Cancer
|
|
BRCA1 mutation
BRCA1 mutation
|
Fallopian Tube Cancer
Fallopian Tube Cancer
|
|
BRCA2 mutation
BRCA2 mutation
|
Fallopian Tube Cancer
Fallopian Tube Cancer
|
|
|
Fallopian Tube Cancer
Fallopian Tube Cancer
|
|
BRCA2 mutation
BRCA2 mutation
|
Fallopian Tube Cancer
Fallopian Tube Cancer
|
|
BRCA1 mutation
BRCA1 mutation
|
Fallopian Tube Cancer
Fallopian Tube Cancer
|
|
No biomarker
No biomarker
|
Fallopian Tube Cancer
Fallopian Tube Cancer
|
carboplatin + micellar paclitaxel
|
BRCA1 mutation
BRCA1 mutation
|
Fallopian Tube Cancer
Fallopian Tube Cancer
|
|
No biomarker
No biomarker
|
Fallopian Tube Cancer
Fallopian Tube Cancer
|
Bevax (bevacizumab biosimilar)
|
BRCA2 mutation
BRCA2 mutation
|
Fallopian Tube Cancer
Fallopian Tube Cancer
|
|
No biomarker
No biomarker
|
Fallopian Tube Cancer
Fallopian Tube Cancer
|
CAPOX
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Fallopian Tube Cancer
Fallopian Tube Cancer
|
sorafenib
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Fallopian Tube Cancer
Fallopian Tube Cancer
|
topotecan
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Fallopian Tube Cancer
Fallopian Tube Cancer
|
pegylated liposomal doxorubicin
Sensitive: A2 - Guideline
|
|
Fallopian Tube Cancer
Fallopian Tube Cancer
|
pembrolizumab
Sensitive: A2 - Guideline
|
NTRK3 fusion
NTRK3 fusion
|
Fallopian Tube Cancer
Fallopian Tube Cancer
|
larotrectinib
Sensitive: A2 - Guideline
|
NTRK2 fusion
NTRK2 fusion
|
Fallopian Tube Cancer
Fallopian Tube Cancer
|
larotrectinib
Sensitive: A2 - Guideline
|
NTRK1 fusion
NTRK1 fusion
|
Fallopian Tube Cancer
Fallopian Tube Cancer
|
larotrectinib
Sensitive: A2 - Guideline
|
NTRK3 fusion
NTRK3 fusion
|
Fallopian Tube Cancer
Fallopian Tube Cancer
|
entrectinib
Sensitive: A2 - Guideline
|
NTRK2 fusion
NTRK2 fusion
|
Fallopian Tube Cancer
Fallopian Tube Cancer
|
entrectinib
Sensitive: A2 - Guideline
|
NTRK1 fusion
NTRK1 fusion
|
Fallopian Tube Cancer
Fallopian Tube Cancer
|
entrectinib
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Fallopian Tube Cancer
Fallopian Tube Cancer
|
etoposide oral
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Fallopian Tube Cancer
Fallopian Tube Cancer
|
trametinib
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Fallopian Tube Cancer
Fallopian Tube Cancer
|
fulvestrant
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Fallopian Tube Cancer
Fallopian Tube Cancer
|
cisplatin + irinotecan
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Fallopian Tube Cancer
Fallopian Tube Cancer
|
albumin-bound paclitaxel
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Fallopian Tube Cancer
Fallopian Tube Cancer
|
pazopanib
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Fallopian Tube Cancer
Fallopian Tube Cancer
|
bevacizumab + niraparib
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Fallopian Tube Cancer
Fallopian Tube Cancer
|
vinorelbine tartrate
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Fallopian Tube Cancer
Fallopian Tube Cancer
|
pemetrexed
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Fallopian Tube Cancer
Fallopian Tube Cancer
|
paclitaxel
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Fallopian Tube Cancer
Fallopian Tube Cancer
|
oxaliplatin
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Fallopian Tube Cancer
Fallopian Tube Cancer
|
melphalan
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Fallopian Tube Cancer
Fallopian Tube Cancer
|
irinotecan
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Fallopian Tube Cancer
Fallopian Tube Cancer
|
ifosfamide
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Fallopian Tube Cancer
Fallopian Tube Cancer
|
doxorubicin hydrochloride
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Fallopian Tube Cancer
Fallopian Tube Cancer
|
cyclophosphamide oral
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Fallopian Tube Cancer
Fallopian Tube Cancer
|
cisplatin
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Fallopian Tube Cancer
Fallopian Tube Cancer
|
capecitabine
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Fallopian Tube Cancer
Fallopian Tube Cancer
|
carboplatin + gemcitabine
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Fallopian Tube Cancer
Fallopian Tube Cancer
|
cisplatin + paclitaxel
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Fallopian Tube Cancer
Fallopian Tube Cancer
|
paclitaxel + ifosfamide
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Fallopian Tube Cancer
Fallopian Tube Cancer
|
cisplatin + ifosfamide
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Fallopian Tube Cancer
Fallopian Tube Cancer
|
carboplatin + ifosfamide
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Fallopian Tube Cancer
Fallopian Tube Cancer
|
carboplatin
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Fallopian Tube Cancer
Fallopian Tube Cancer
|
tamoxifen
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Fallopian Tube Cancer
Fallopian Tube Cancer
|
leuprolide acetate
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Fallopian Tube Cancer
Fallopian Tube Cancer
|
exemestane
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Fallopian Tube Cancer
Fallopian Tube Cancer
|
letrozole
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Fallopian Tube Cancer
Fallopian Tube Cancer
|
anastrozole
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Fallopian Tube Cancer
Fallopian Tube Cancer
|
carboplatin + docetaxel
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Fallopian Tube Cancer
Fallopian Tube Cancer
|
carboplatin + pegylated liposomal doxorubicin
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Fallopian Tube Cancer
Fallopian Tube Cancer
|
5-fluorouracil + oxaliplatin
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Fallopian Tube Cancer
Fallopian Tube Cancer
|
carboplatin + paclitaxel
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Fallopian Tube Cancer
Fallopian Tube Cancer
|
BEP
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Fallopian Tube Cancer
Fallopian Tube Cancer
|
VAC
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Fallopian Tube Cancer
Fallopian Tube Cancer
|
EP
Sensitive: A2 - Guideline
|
|
Fallopian Tube Cancer
Fallopian Tube Cancer
|
pembrolizumab
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Fallopian Tube Cancer
Fallopian Tube Cancer
|
bevacizumab + olaparib
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Fallopian Tube Cancer
Fallopian Tube Cancer
|
cisplatin + gemcitabine
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Fallopian Tube Cancer
Fallopian Tube Cancer
|
OMP-305B83
Sensitive: B - Late Trials
|
HRD + BRCA2 mutation
HRD + BRCA2 mutation
|
Fallopian Tube Cancer
Fallopian Tube Cancer
|
niraparib
Sensitive: C3 – Early Trials
|
HRD + BRCA1 mutation
HRD + BRCA1 mutation
|
Fallopian Tube Cancer
Fallopian Tube Cancer
|
niraparib
Sensitive: C3 – Early Trials
|
TUBB3 expression
TUBB3 expression
|
Fallopian Tube Cancer
Fallopian Tube Cancer
|
bevacizumab + ixabepilone
Resistant: C3 – Early Trials
|
